Sector Pharmaceuticals & Biotech. - Latest news, views and updates

SECTOR | 30 Jan 2025

Laurus Labs share price zooms 10% after getting THIS US relief. Do you own?

livemint

Laurus Labs stock declined by more than 15 per cent on Monday following the U.S. government's directive to halt the President's Emergency Plan for AIDS Relief (PEPFAR), which would have disrupted the supply of antiviral medications for millions.

Laurus gains 15% in 2 days on robust CDMO outlook; updates on AIDS drug biz

Business Standard | 30 Jan 2025

Pharmaceuticals & Biotech.

SECTOR | 28 Jan 2025

Diversified model should help sustain US business: Cipla MD

Business Line

US administration has paused funding to global AIDS programme and mulls higher tariffs on pharmaceuticals

Pharmaceuticals & Biotech.

SECTOR | 27 Jan 2025

Laurus Labs Sees No Significant Impact From US Pausing Funds For AIDS Relief

NDTV Profit

If at all there may be funding challenge, the company reasonably believes it will not affect the procurement of medications, Laurus Labs said.

Pharmaceuticals & Biotech.

SECTOR | 24 Jan 2025

Lupin receives USFDA approval to market its generic HIV medications

Business Standard

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets, the Mumbai-base drug maker said in a statement. The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension, it added. This product would be manufactured at the drug firm's Nagpur facility and will be supplied to low-and middle-income countries, it said. The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg. "The tentative approval from the USFDA for our Abacavir, Dolutegravir and

Pharmaceuticals & Biotech.

SECTOR | 22 Jan 2025, 05:49PM

Trump era begins with disappearance of reproductive rights website

Business Standard

Launched by the Biden administration in 2022, the site offered vital information on abortion, cancer screenings, prenatal care, and HIV testing

Pharmaceuticals & Biotech.

SECTOR | 21 Jan 2025, 07:00AM

Pharma sector MFs led the pack last year. Here are the pharma stocks powering them

Business Line

Funds with higher allocation to mid- and small-cap pharma players delivered better returns

Pharmaceuticals & Biotech.

SECTOR | 17 Jan 2025

Medical-device industry divided on Health Ministry clarification ending import of refurbished items

Business Line

CDSCO stated that such products cannot be imported to India given the absence of specific regulatory provisions

Pharmaceuticals & Biotech.

SECTOR | 17 Jan 2025

India's push for self-reliance: Medical devices sector shows promising growth

Business Line

The data shows India's medical devices sector is gradually achieving self-reliance in consumables, implants, and electronic equipment, though import dependency remains high in some areas

Pharmaceuticals & Biotech.

SECTOR | 11 Jan 2025

Banking on Pharma

Business Line

Pharma sector attracts investor attention in a period of volatility

IT services, Pharma sector PAT to grow by 5.8% in Q3FY25: JM Financial

Business Line | 11 Jan 2025

Pharmaceuticals & Biotech.

SECTOR | 08 Jan 2025

What's In Store For IT, Cement, O&G, Auto, Pharma Sector & More Ahead Of Q3 Results: Motilal Oswal's Analysis

NDTV Profit

Q3 FY25 Results Preview - In large caps Motilal Oswal lists ICICI Bank, Airtel, Sun Pharma and in mid caps bets on Angel One, Coforge, Cummins among others as its top stock picks.